Tower One Wireless Corp (TOWTF)

[Grolden]

Jan 8, 2015 Shareholder Update for 2015

To date Pacific has completed phase 1 clinical and preclinical studies in its process to commercialize PTL-202 its lead candidate for treatment of fibrosis specifically Idiopathic Pulmonary Fibrosis. In the clinical study the interaction of the drugs in the combination showed a positive interaction that will result in patients requiring smaller doses of PTL-202. The preclinical studies demonstrated that the combination of the drugs in PTL-202 was more effective than the individual components at reducing inflammation and fibrosis in the animal studies. During 2014 the patent covering the technology in PTL-202 was approved in Europe. Pacific will continued with the prosecution process of this patent in additional countries including the USA.

There have been many positive industry events concerning IPF during 2014, including the $8.3 billion acquisition of InterMune by Roche Holdings to gain access to the approved IPF therapy Prifenidone and the recent option agreement signed by Bristol Myers Squibb to purchase Galecto of Denmark for $444 million. Galecto’s treatment for IPF is about to start a phase 1 trial. Given big pharma’s interest in the fibrosis space and earlier stage therapies Pacific will seek out a strategic partner for the continued development and commercialization of PTL-202.

The next step in the development of PTL-202 is the initiation of a phase 1b dose ranging study in humans. This study is planned for 2015 and will be followed by a phase 2 proof of concept study beginning in 2016.

In Q4 of 2013 Pacific acquired the rights to complete the development and commercialize worldwide a new formulation of sildenafil for erectile dysfunction. This reformulation, PTL-2015, of an existing drug may reduce the side effects and speed the onset associated with current formulations of sildenafil. Pacific is now set to conduct a pivotal bioequivalence study beginning in the first quarter of 2015. Data from this study will be used to apply for marketing approval of PTL-2015 in Europe.

During 2015 Pacific will seek out a commercialization partner in Europe for PTL-2015.

During Q4 of 2013 Pacific’s 20-f registration was accepted by the SEC in the United States. In Q2 2014 FINRA approved Pacific for listing on the OTCBB and issued it’s US trading symbol PCFTF. Pacific enlisted Vstock Transfer as its transfer agent in the United States and began trading in Q2 2014. The company applied for and received DTC eligibility in Q4 of 2014 providing United States investors greater access to Pacific shares. Pacific plans to strengthen its balance sheet in 2015 with additional financing in the first quarter to complete the development and commercialization of PTL-2015 for ED and initiate the dose ranging study of PTL-202 for IPF.

In addition Pacific will focus on increasing its shareholder base during 2015, and work diligently to increase its net asset value to be eligible for a listing on a national stock exchange in the USA. Along with these initiatives, Pacific will increase its focus on institutions and funds that focus in the biotech and healthcare industry. In addition, the Company will execute a parallel path of stronger fundamentals coupled with a proactive campaign to not only focus on institutional investors but also retail, accredited investors, high net worth family office as well as wall street and industry analysts.

The final area of focus for 2015 will be building the team at Pacific. Internally, the Company will look to build its management and Board of Directors to help guide the Company from the OTCBB to a National Exchange. Externally, the Company is currently working with a select group of advisors in the areas of M&A, business development and collaborations that should accelerate the clinical work and potential licensing and revenue generating initiatives. The Company is currently evaluating business and advisory firms to help navigate through the regulatory process and advise senior management in multiple areas that would increase shareholder value in the 2015 and beyond.